Discontinued — last reported Q4 '17
An increase indicates strong performance from strategic partners or joint ventures, while a decrease signals underperformance or losses within the company's collaborative investment portfolio.
This metric captures the company's proportional share of the net income or loss generated by entities in which it holds...
Similar to equity income reported by other global pharmaceutical firms that utilize joint ventures for drug development and regional market expansion.
mrk_segment_operating_segments_income_loss_from_equity_method_investments